Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s140, 2023. DOI: 10.25251/skin.7.supp.140. Disponível em: https://skin.dermsquared.com/skin/article/view/2029. Acesso em: 18 apr. 2025.